Six London companies have triumphed at the 2nd Mayor of London MedTech Business awards, which was held at Hill Dickinson’s offices in London on Tuesday 30th April.

The award-winners include a Responder app, mental health app, medical device for cancer research, AI to teach emergency life-savings skills, medical device developing magnetic blood filtration, global health tech firm.

The awards are part of the Mayor of London’s annual MedTech Conference, run by MedTech London, a business support initiative run by the South East Health Technologies Alliance (SEHTA) in collaboration with MedCity, funded by the Mayor of London.

MedTech London also publish a MedTech London Review and Directory, which was launched at the event. It examines trends in the industry and provides the first database of the over 350 medical tech firms in the capital. Please click here to complete a survey in order to receive your copy.

Five of the award winners will be entered in to the National MedilinkUK Awards in NCC Birmingham on the 15th May, which is part of the Med-Tech Expo 2019:

Export Award: GoodSAM

GoodSAM is a global community of over 50,000 off-duty doctors, nurses, police/fire officers, first aiders, volunteering to be alerted by the GoodSAM Responder app on their smartphone phone to cardiac arrests.

Innovation Award: MeeTwo

The MeeTwo app is a best practice example of a safe, scalable way to deliver fast, effective mental help to vulnerable young people. It combines the best aspects of peer support with the added benefits of expert guidance.

Partnership with the NHS Award: C the Signs

C the Signs is a class 1 Medical device with CE marking. The tool uses artificial intelligence mapped with the latest research to accelerate early identification and management of patients at risk of cancer.

Start-up Award: Virti

Virti uses virtual and augmented reality combined with artificial intelligence to transport users into realistic, hard-to-access environments and safely assesses them under pressure to improve human performance and outcomes regardless of geographical boundaries to teach emergency life-saving skills.

Investment Achievement Award: MediSieve

MediSieve is a medical device therapeutics company developing “magnetic blood filtration”, a revolutionary method of treating blood-borne diseases by removing pathogens directly from a patient’s bloodstream.

Outstanding Achievement Award: Medopad

Medopad is a global health technology company that aims to help more than1 billion people live longer by enabling continuous patient monitoring and communications. By partnering with the world’s largest healthcare systems, pharma companies, research institutes, insurers and technology companies like Apple and Tencent, Medopad is creating a connected health ecosystem that empowers patients, improves clinical outcomes and enables the future of healthcare.

 The runners-up were:

Rajesh Agrawal, Deputy Mayor for Business, said: “London is home to some of the most innovative medical technology companies in the world. Not only do these businesses provide high-skilled jobs and boost our economy, they also develop lifesaving products. We know that our health service is under more and more pressure, so innovation and fresh thinking like this is vital”.

Dr David Parry, CEO, SEHTA said; “We are proud to be part of the 2nd Mayor of London MedTech Business Awards.  We had a record number of entries from London-based companies and the competition was intense demonstrating the excellence of small health technology companies in the capital.  It’s a primary aim of SEHTA to help such companies’ access public and private sector markets with their innovative products and services”.

 Phil Jackson, Projects Director at MedCity, who was part of the judging panel said: “These awards demonstrate the scale and range of MedTech companies in the capital, that form part of our world-leading life sciences sector. One thing that stood out to me is the collaborations across industry, academia, the NHS, and patients, which has made these the innovative, successful products they are”.